Last reviewed 2026-05-28 · How we verify

Weekly Oral Cyclic Antibiotic programme

University Hospital, Tours · FDA-approved active Small molecule ✓ Verified May 2026 Quality 0/100

Weekly Oral Cyclic Antibiotic programme is a Small molecule drug developed by University Hospital, Tours. It is currently FDA-approved.

A Weekly Oral Cyclic Antibiotic programme is a treatment intervention studied for conditions such as Neurogenic Bladder and Urinary Tract Infection. This programme involves administering antibiotics on a weekly cycle, but its mechanism of action is not related to inducing an immune response as a vaccine component.

At a glance

Generic name	Weekly Oral Cyclic Antibiotic programme
Sponsor	University Hospital, Tours
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Weekly Oral Cyclic Antibiotic programme CI brief — competitive landscape report
Weekly Oral Cyclic Antibiotic programme updates RSS · CI watch RSS
University Hospital, Tours portfolio CI

Frequently asked questions about Weekly Oral Cyclic Antibiotic programme

What is Weekly Oral Cyclic Antibiotic programme?

Weekly Oral Cyclic Antibiotic programme is a Small molecule drug developed by University Hospital, Tours.

Who makes Weekly Oral Cyclic Antibiotic programme?

Weekly Oral Cyclic Antibiotic programme is developed and marketed by University Hospital, Tours (see full University Hospital, Tours pipeline at /company/university-hospital-tours).

What development phase is Weekly Oral Cyclic Antibiotic programme in?

Weekly Oral Cyclic Antibiotic programme is FDA-approved (marketed).

Manufacturer: University Hospital, Tours — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing